Silverarc Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Silverarc Capital Management’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-419,949	Closed	-$2.55M	–	83
2026 Q1	$3.22M	Buy	419,949 +25,299	+6%	+$235K	0.33%	50
2025 Q4	$4.46M	Buy	+394,650	New	+$4.02M	0.62%	42
2024 Q3	–	Sell	-398,436	Closed	-$2.47M	–	75
2024 Q2	$2.47M	Hold	398,436	–	–	0.58%	50
2024 Q1	$3.76M	Buy	+398,436	New	+$3.56M	1.04%	30
2021 Q4	–	Sell	-185,691	Closed	-$5.24M	–	80
2021 Q3	$5.24M	Buy	+185,691	New	+$3.52M	2.96%	9
2021 Q2	–	Sell	-121,302	Closed	-$1.43M	–	106
2021 Q1	$1.43M	Buy	121,302 +105,093	+648%	+$1.3M	0.78%	47
2020 Q4	$190K	Buy	+16,209	New	+$183K	0.11%	80

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Silverarc Capital Management's FULC Position: Q2 2026 in Review

Silverarc Capital Management sold out of Fulcrum Therapeutics (FULC) in Q2 2026, closing a stake of 419,949 shares — an estimated $2.55M sold.

Silverarc Capital Management first reported a position in FULC in Q4 2020 and held it in 7 quarters. The position peaked at $5.24M in Q3 2021. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

Silverarc Capital Management reported no remaining Fulcrum Therapeutics position as of Q2 2026 after selling out during the quarter.
Silverarc Capital Management sold 419,949 Fulcrum Therapeutics shares in Q2 2026, an estimated $2.55M.
Silverarc Capital Management first reported a position in Fulcrum Therapeutics in Q4 2020 and held it in 7 quarters.
Silverarc Capital Management's Fulcrum Therapeutics position peaked at $5.24M in Q3 2021.
155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.